Pompe Workshop Report Allan Muir, Pompe Representative, AGSD(UK) On October the 16th this year we held our annual AGSD (UK)

Dear IPA members, Pompe patients, family members and GSD-net participants, The IPA board received several questions concerning participation in the

Genzyme Corp. (Nasdaq: GENZ) announced today that the Food and Drug Administration has granted marketing approval for Myozyme® (alglucosidase alfaA form of enzyme replacement therapy used to treat Pompe disease by providing a lab-made version of the GAA enzyme.)

Product is First Treatment for Pompe DiseaseA rare genetic disease in which the body cannot properly break down glycogen, leading to buildup that damages muscles and can affect breathing and, in some cases, the heart. Genzyme Corp. (Nasdaq: GENZ) announced today that it has received marketing authorization for

Genzyme Corp. (Nasdaq: GENZ) announced today that the Food and Drug Administration has extended by 90 days the review period

The IPA has developed the Pompe connections brochure to help get patients and their families timely and relevant information about

Genzyme Corp. (Nasdaq: GENZ) announced today that it has submitted a biologics license application (BLA) to the U.S. Food and

May 11th 2005 IPA Conference Pompe’s disease Nantes, France. “Emerging therapies for Pompe disease” Dr. Ans van der Ploeg, Erasmus

CAMBRIDGE, Mass.—Genzyme Corp. (Nasdaq: GENZ) announced today that it has completed a planned analysis of interim data from its pivotal

CAMBRIDGE, MA—Genzyme Corp. (Nasdaq: GENZ) announced today that the European Medicines Agency (EMEA) has accepted its marketing authorization application for